Since its establishment in 2013, PBI has been active in delivering research papers and oral presentations to the scientific and medical community. PBI has been invited to deliver diverse presentations and act as session chair at conferences and meetings; and has been successful in securing a significant number of awards. Additionally, PBI has been recognised for our high scoring and accepted abstracts, a significant achievement for an emerging research institute. 

Research Papers


Baker, R.I., Gilmore, G., Chen, V., et al. Direct oral anticoagulants or Vitamin K antagonists in emergencies: comparison of management in an observational studyResearch and Practice in Thrombosis and Haemostasis (2023), doi:


Capra, M., Martin, T., Moreau, P., Baker, R. Pour, L., Min, C., Leleu, X., Mohty, M., Reinoso Segura, M., Turgut, M., Leblanc, R., Risse, M.,  Malinge, L., Schwab, S., Dimopoulos, M.A. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: Ikema Subgroup AnalysisHaematologica. 2022 Jun 1;107(6):1397-1409. doi: 10.3324/haematol.2021.279229.

Elaskalani, O., Gilmore, G., Hagger, M., Baker, R.I., and Metharom, P. Adenosine 2A receptor activation amplifies ibrutinib antiplatelet effect; implications in chronic lymphocytic leukemia. Cancers (Basel). Nov 2022;14(23):5750. doi: 10.3390/cancers14235750.

Fogarty, H., Ward, S.E., ..... Baker, R.I., Cheallaigh, C.N., O'Donnell, J.S. Sustained VWF‐ADAMTS‐13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunctionJ Thromb Haemost. 2022 Oct;20(10):2429-2438. doi: 10.1111/jth.15830.

Dimopoulos, M.A., Voorhees, P.M., Goldschmidt, H., Baker, R.I., Shi, Y., Rousseau, E., Dennis, R.M., Carson, R.L., Rajkumar, S.V. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA studyJournal of Clinical Oncology 40.16_suppl (2022): TPS8075–TPS8075. Web.

Kuter, D.J., Efraim, J., ..... Baker R., et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaN Engl J Med. 2022; 386:1421-1431. DOI: 10.1056/NEJMoa2110297

Lavin, M., Sánchez Luceros, A., Kouides, P., Abdul-Kadir, R., O’Donnell, J.S., Baker, R.I., Othman, M., Haberichter, S.L. Examining international practices in the management of pregnant women with von Willebrand disease. J Thromb Haemost. 2022;20:82–91

Kalot, M.A., Husainat, N., El Alayli, A., Abughanimeh, O., Diab, O., Tayiem, S., Madoukh, B., Dimassi, A.B., Qureini, A., Ameer, B., Eikenboom, J.C.J., Giraud, N., McLintock, C., McRae, S. et al. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Advances 2022; 6(1): 62-71. DOI 10.1182/bloodadvances.2021005430.

Lim, M.S., Hayes, R., Sharma, A., Kitiponchai, T., Mohamed, M., & McRae, S. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples. Pathology 2022; 54(5): 599-605. DOI:10.1016/j.pathol.2022.01.00

Hart, D.P., Matino, D., Astermark, J., Dolan, G., d’Oiron, R., Hermans, C., Jiménez-Yuste, V., Linares, A., Matsushita, T., McRae, S., Ozelo, M.C., Platton, S., Stafford, D., Sidonio Jr. R.F., & Tiede, A. International consensus recommendations on the management of people with haemophilia B. Therapeutic advances in hematology 2022; 13: 1–22. DOI: 10.1177/ 20406207221085202


Baker, R.I. & O'Donnell, J.S. How I treat bleeding disorder of unknown cause. Blood. 2021 Nov; 138(19): 1795-1804.

Kuter. D.J., Tzvetkov, N., Efraim, M., Kaplan, Z., Mayer, J., Choi, P., Jansen, A.J.G., McDonald, V., Baker, R. et al. Updated phase I/II safety and efficacy results for oral bruton tyrosine kinase inhibitor rilzabrutinib in patients with relapsed/refractory immune thrombocytopenia. Blood. 2021 Nov; 138(Supplement 1):14-14. DOI:10.1182/blood-2021-145128.

Wines, B.D., Trist, H.M., Esparon, S., Impey, R.E., Mackay, G.A., Andrews, R.K., Soares da Costa, T.P., Pietersz, G.A., Baker, R.I., and Hogarth, P.M. Fc binding by FcγRIIa is essential for cellular activation by the anti-FcγRIIa mAbs 8.26 and 8.2. Front. Immunol. 12:666813.
doi: 10.3389/fimmu.2021.666813

Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, Englert H, Byrne M, Bergin C, O’Sullivan JM, Martin-Loeches I, Nadarajan P, Bannan C, Mallon PW, Curley GF, Preston RJS, Rehill AM, McGonagle D, Cheallaigh CN, Baker RI, Renné T, Ward SE, O’Donnell JS, the Irish COVID-19 Vasculopathy Study (iCVS) investigators. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021 Oct; 19(10): 2546-2553.

Ward SE, Fogarty H, Karampini E, Lavin M, Schneppenheim S, Dittmer R, Morrin H, Glavey S, Cheallaigh CN, Bergin C, Martin-Loeches I, Mallon PW, Curley GF, Baker RI, Budde U, O’Sullivan JM, O’Donnell JS, the Irish COVID-19 Vasculopathy Study (iCVS) investigators. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021 Aug; 19(8): 1914-1921.

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min C, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021 June; 397(10292): 2361-2371.

Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang M, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Mongay Soler L, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology 2021 May; 22(5): 678–89.

Tian J, Adams MJ, Tay J.W.T, James I, Powell S, Hughes QW, Gilmore GBaker RI, Tiao JY-HEstradiol-responsive miR-365a-3p interacts with tissue factor 3′UTR to modulate tissue factor-initiated thrombin generation. Thromb Haemost 2021 Feb (online).

Lim, M.S., & Mcrae, S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology 2021; 168.

James, P.D., Connell, N.T., Ameer, B., Di Paola, J., Eikenboom, J., Giraud, N., Haberichter, S., Jacobs-Pratt, V., Konkle, B., McLintock, C., McRae, S. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances 2021; 5 (1): 280-300. DOI 10.1182/bloodadvances.2020003265.


Mackie I, Mancini I, Muia J, Kremer Hovinga J, Nair S, Machin S, Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hemat 2020 Dec: 42(6): 685-696.

Nagler MHendriks T, McGregor S, Rakesh S, Robinson J, Ho KM, Baker RPatient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The Swan Study. PLoS ONE 2020 Jun; 15(6): e0234048.

Favaloro EJ, Gilmore G, Bonar RDean E, Arunachalam S, Mohammed S, Baker R. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia 2020 March; 26(2): 354-362.

Favaloro EJGilmore GBonar R, Dean E, Arunachalam S, Mohammed S, Baker R. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interferenceClinical Chemistry and Laboratory Medicine 2020; 58(8).

Tiao J, Powell S, Gilmore G, Veedu R, Wilton S, Baker R. Splice inducing Antisense Oligonucleotides as a potential gene correction therapy for haemophilia A. Haemophilia 2020; 26(S4): 21-22.

Brennan, Y., Parikh, S., McRae, S., & Tran, H. The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation. Haemophilia 2020; 26:529–535.

Click HERE for research publications from 2013 -2019